720-550-6175 Contact

Apeiron Research Center · 501(c)(3) non-profit

Clinical trials.

The Apeiron Research Center, founded by Dr. Glowney, runs IRB-approved clinical trials of autologous bone marrow–derived biologics. Each study is registered with ClinicalTrials.gov, the U.S. National Library of Medicine's public registry. Below is a summary of each one, with a link to its full registry record.

Summarized from ClinicalTrials.gov · October 2, 2026. The registry record is the authoritative source for current status and eligibility.

NCT07751640 · SPARC-PD Active, not recruiting

A pilot study in Parkinson's disease and Parkinson-plus syndromes.

Registered title: Autologous Bone Marrow Aspirate (IV) and Bone Marrow Concentrate (Intranasal) for Parkinson's Disease and Parkinson-Plus Syndromes (SPARC-PD)

A pilot study of a single, same-day procedure. Bone marrow is drawn from the back of the hip under local anesthesia. Part of it is filtered and given intravenously (BMA); part is concentrated in the lab and delivered as a fine intranasal mist (BMAC). The cells are the participant's own, and are not expanded in culture or genetically modified.

The main question is safety and tolerability. The study also looks at blood-based measures of biological age and at the makeup of the cells that were delivered.

PhasePhase 1 / 2a pilot
DesignSingle-arm, open-label; each participant is their own control
Enrollment10 participants (enrollment complete)
Ages40 to 85
StartedMay 2025
Est. completionSeptember 2026
Principal investigatorJason Glowney, MD, MSc
SponsorApeiron Research Center

What the study measures

  • Primary: treatment-related adverse events, graded on the standard NCI (CTCAE v5.0) scale, from baseline through 12 months.
  • Biological age: DNA-methylation “clocks” (GrimAge and organ-system Systems Age) from a blood draw at baseline and about 6 months.
  • The delivered cells: concentration, viability, and dose of mesenchymal stromal cells, measured by flow cytometry.
  • Symptoms and function: standard Parkinson's motor, non-motor, cognitive, and quality-of-life scales, plus gait and sit-to-stand tests.
Full record on ClinicalTrials.gov →

Last updated on the registry August 7, 2026.

NCT06858254 · SO-ASC-INIVAT Not yet recruiting

Intranasal and intravenous delivery in Parkinson's disease and atypical parkinsonism.

Registered title: Standard Optimization of Autologous Stem Cells by Intranasal and Intravenous Administration to Treat Parkinson's Disease and Atypical Parkinsonism

A randomized crossover study comparing intranasal and intravenous delivery of the participant's own bone marrow–derived biologics, measuring effects on motor and non-motor function. It is a collaboration with the University of Colorado Boulder.

Participants attend seven scheduled visits over 18 months, every three months, alternating in-person and remote. At the first two treatment visits (day 0 and 6 months), each participant receives one route and a sham of the other, in a randomized order. At 12 months, everyone receives both.

PhasePhase 1 / 2
DesignRandomized crossover; participant-blinded
Planned enrollment60 participants (40 Parkinson's, 20 Parkinson-plus)
Ages40 to 75
Duration18 months per participant
Est. completionApril 2028
Principal investigatorJason Glowney, MD, MSc
Sponsor · collaboratorApeiron Research Center · University of Colorado Boulder

What the study measures

  • Motor function: MDS-UPDRS Part III motor exam, 10-meter walk, five-times sit-to-stand, Mini-BESTest balance, and Hoehn & Yahr stage.
  • Cognition: Montreal Cognitive Assessment (MoCA), among other standardized scales.
  • Brain activity: resting and task-based functional MRI.

The registry lists the full inclusion and exclusion criteria, including diagnosis within the past six years. The research team reviews eligibility with each person individually.

Full record on ClinicalTrials.gov →

Last updated on the registry March 5, 2025.

These are investigational studies of uses that are not FDA-approved. Intranasal delivery remains investigational and is not FDA-approved for neurological disease. Titles are shown as registered; the Apeiron Research Center is a separate non-profit from the Boulder Biologics clinic, and trial participation follows IRB-approved protocols and informed consent.

Questions about a study?

Contact us and we'll connect you with the research team. You can also learn more about the Research Center itself.

Contact us → Apeiron Research Center